Artios
- Headquarters
- Cambridge
- Employees
- 51–200
- Founded
- 2016
- Website
- artios.com
- Total Funding
- $115.0M
- Last Round
- $115.0M Series DNov 2025
About
Artios is a clinical-stage biopharmaceutical company focused on developing cancer therapies that target the DNA Damage Response pathway. Based at the Babraham Campus in Cambridge, UK, it has built a pipeline of DDR inhibitors including alnodesertib (ATR inhibitor) and a Pol Theta inhibitor program. Co-founded in 2016 by pioneering DDR researchers, Artios raised $115M in a Series D in 2025.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account